Earnings Standouts: 52 Stocks Outperforming Wall Street Estimates
Research by the Bank for International Settlements said that equity markets tend to already price in earnings expectations well before official results are announced.
Bio-Rad Laboratories Inc. (BIO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | First Eagle Investment Management Jean-Marie Eveillard | 2,606,219 | $765,211,916 | +1% | 1.28% |
| 2. | Fisher Asset Management Ken Fisher | 116,909 | $34,325,650 | -2% | 0.01% |
| 3. | Hosking Partners Jeremy Hosking | 94,430 | $27,725,592 | +37% | 0.92% |
| 4. | Skylands Capital Charles Paquelet | 7,225 | $2,121,332 | +28% | 0.26% |
| 5. | Bayforest Capital Theodoros Tsagaris | 682 | $200,242 | 0.19% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $219.58 | 500 | $109,792.45 | 500 | 2017-05-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $246.54 | 550 | $135,597.00 | 346 | 2026-05-11 | Filing | |
| $306.18 | 700 | $214,288.51 | 510 | 2025-11-06 | Filing | |
| $247.06 | 3,000 | $741,184.20 | 8,171 | 2025-03-14 | Filing | |
| $329.94 | 3,000 | $989,815.20 | 7,559 | 2024-09-06 | Filing | |
| $330.49 | 623 | $205,898.14 | 147 | 2024-09-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 233,227 | $68,477,779 | 0.09% | |
| 2. | 113,854 | $33,428,798 | 0.01% | |
| 3. | 111,167 | $32,639,743 | 0.25% | |
| 4. | 105,449 | $30,960,831 | 0.01% | |
| 5. | 72,116 | $21,173,979 | 0.1% |
News See All
Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out
Ariel Investments, an investment management company, released its “Ariel Focus Fund" Q1 2026 Investor Letter. A copy of the letter can be downloaded here.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2026 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. My name is Regina, and I will be your conference operator today.
Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns
TheFly reported on April 7 that Citigroup lowered its rating on BIO from Buy to Neutral and reduced its price target from $375 to $300.
9 Most Undervalued Healthcare Stocks to Buy Now
On April 17, Matt Powers, managing partner at Powers Advisory Group, appeared on CNBC’s Squawk Box to discuss the forces shaping current market behavior.
Artisan Mid Cap Value Fund Sold Bio-Rad Laboratories (BIO) in Q4
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Value Fund”. A copy of the letter can be downloaded here.
Disappointing Results Hurt Bio-Rad Laboratories (BIO)
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf Partners Global Fund”. A copy of the letter can be downloaded here.
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth
Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc.
10 Best Debt-Free Mid-Cap Stocks to Buy According to Hedge Funds
Mid-cap stocks are poised for an impressive run heading into the US midterm election.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I would like to hand things over to Mr. Edward Chung.
Hedge Fund Resource Center